Kunming Biomed International
Kunming Biomed International (KBI) is a world leading CRO providing preclinical research services that specialized in nonhuman primates (NHPs). Led by an experienced international team, KBI has collaborated with over 18 large pharmas using translational NHP models for pharmacological efficacy and safety evaluations, including NASH/fibrosis, diabetes and diabetic complications (nephropathy, retinopathy), and cardiovascular diseases (dyslipidemia, heart failure), etc. KBI has state-of-the-art AAALAC accredited animal research facilities, and extensive colonies (>6000) of healthy and diseased models.